Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti-apoptotic proteins, including BCL-XL and MCL-1. Unfortunately, the currently available inhibitors of BCL-2 family anti-apoptotic proteins, except BCL-2 inhibitors, are not clinically relevant because of various on-target toxicities. We, therefore, aimed to develop an effective and safe strategy targeting these anti-apoptotic proteins with DT2216 (our platelet-sparing BCL-XL degrader) and AZD8055 (an mTOR inhibitor) to avoid associated on-target toxicities while synergistically optimizing tumor response. Through BH3 mimetic screening, we identified a subset of SCLC cell lines that is co-dependent on BCL-XL and MCL-1. After screening inhibitors of selected tumorigenic pathways, we found that AZD8055 selectively downregulates MCL-1 in SCLC cells and its combination with DT2216 synergistically killed BCL-XL/MCL-1 co-dependent SCLC cells, but not normal cells. Mechanistically, the combination caused BCL-XL degradation and suppression of MCL-1 expression, and thus disrupted MCL-1 interaction with BIM leading to an enhanced apoptotic induction. In vivo, the DT2216 + AZD8055 combination significantly inhibited the growth of cell line-derived and patient-derived xenografts and reduced tumor burden accompanied by increased survival in a genetically engineered mouse model of SCLC without causing appreciable thrombocytopenia or other normal tissue injuries. Thus, these preclinical findings lay a strong foundation for future clinical studies to test DT2216 + mTOR inhibitor combinations in a subset of SCLC patients whose tumors are co-driven by BCL-XL and MCL-1.
Small-cell lung cancer (SCLC) is a difficult-to-treat subtype of pulmonary carcinomas with a 5-year survival rate of ~5% and median survival of less than a year [1, 2]. First-line treatment for SCLC with combinations of a platinum-based agent (cisplatin or carboplatin) and etoposide (a topoisomerase-II inhibitor) has remained largely unchanged for almost 35 years. Recently, a triplet of atezolizumab (a PD-L1 antibody), carboplatin, and etoposide was approved as first-line therapy for extensive-stage SCLC but provides only a moderate (~2 months) increase in overall survival compared to chemotherapy alone [3, 4]. More importantly, the SCLC tumors are initially responsive to chemotherapy, however, relapse occurs in a majority (>80%) of cases, and there is no effective second-line treatment for relapsed SCLC [4, 5]. There is thus an urgent and unmet need to find newer treatment strategies to effectively treat SCLC.
SCLC has historically been treated as a homogeneous disease. However, it has been recently demonstrated that inter- and intra-tumoral heterogeneity occurs in SCLC, is primarily responsible for reduced therapeutic efficacy and resistance [6,7,8,9]. Since unique resistance mechanisms occur in response to specific therapies, specific oncoproteins and/or pathways need to be defined and targeted for effectively treating SCLC. Aberrant expression of anti-apoptotic BCL-2 family proteins has also been shown to account for intratumoral heterogeneity and therapeutic resistance in SCLC [6, 10]. This has been therapeutically exploited with a dual BCL-XL/BCL-2 inhibitor ABT263 (navitoclax) that shows high efficacy in preclinical models of SCLC [11, 12]. Unfortunately, the single-agent efficacy of navitoclax against SCLC in phase-II clinical trials was limited  because of the intratumoral heterogeneity and dependence of some of the cells within a tumor on other BCL-2 family proteins such as MCL-1. More importantly, the clinical use of ABT263 is hampered by dose-limiting severe thrombocytopenia caused by BCL-XL inhibition [14, 15]. We are now able to safely target BCL-XL using proteolysis targeting chimeras (PROTACs, such as DT2216) without causing appreciable platelet toxicity (thrombocytopenia) as recently reported by our group [16,17,18,19,20].
In this study, we aimed to develop a synergistic and safe therapeutic strategy for SCLC. This was achieved first by profiling the heterogeneity of survival dependence of a panel of SCLC cell lines on the BCL-2 family anti-apoptotic proteins by BH3 mimetic screening, where we used BH3 mimetics to target specific BCL-2 anti-apoptotic proteins followed by measurement of cell viability . We defined a subset of SCLC cell lines that are co-dependent on BCL-XL and MCL-1 for survival and focused on testing the ability to target these cell lines effectively and safely. Currently, such tumors cannot be safely targeted with available inhibitors. For example, MCL-1 inhibition causes severe cardiotoxicity, and co-targeting BCL-XL and MCL-1 with commercially available inhibitors further exacerbates normal tissue injury and causes lethality [22,23,24]. Therefore, we need to develop an alternate strategy to selectively suppress BCL-XL and MCL-1 in co-dependent SCLC tumors to avoid their on-target and dose-limiting toxicities. We have devised a safer strategy to target these tumors as we found that BCL-XL/MCL-1 co-dependent SCLC cells can be synergistically killed with a combination of DT2216 (a selective BCL-XL PROTAC degrader) and AZD8055 (an mTOR inhibitor). This was achieved by selective degradation of BCL-XL and inhibition of MCL-1 expression in tumor cells with DT2216 and AZD8055, respectively, therefore reducing on-target toxicity to platelets and other normal cells. In vivo, the combination of DT2216 and AZD8055 strongly inhibited the growth of cell line-derived and patient-derived xenograft (PDX) tumors and reduced tumor burden as well as increased survival of a murine Rb1/p53/p130 SCLC genetically engineered mouse (GEM) model without causing appreciable thrombocytopenia or other normal tissue injuries.
BH3 mimetic screening identifies DT2216 sensitive and resistant SCLC cells in vitro
We first explored the mRNA expression of anti-apoptotic BCL-2 family genes in patient tumors via cBioPortal . These data showed that BCL2, BCL2L1 (BCL-XL coding gene), MCL1, and BCL2A1 (BFL-1 coding gene) are abundantly expressed in most SCLC patients’ tumors (Fig. 1a). Unfortunately, no healthy lung tissue transcriptomics data were available for a side-by-side comparison to show whether or not these genes were overexpressed in SCLC. Therefore, to establish the importance of these BCL-2 family of anti-apoptotic proteins in SCLC, we systematically evaluated the effects of inhibitors of BCL-2 family anti-apoptotic proteins, i.e., A1155463 (a selective BCL-XL inhibitor), venetoclax (a selective BCL-2 inhibitor), S63845 (a selective MCL-1 inhibitor) and navitoclax (a BCL-XL/BCL-2 inhibitor) on the viability of a panel of 20 SCLC cell lines, which was named as the BH3 mimetic screening . The cell lines with EC50 < 1 µM for a particular inhibitor were considered sensitive. SCLC cell lines showed differential dependence on different BCL-2 family anti-apoptotic proteins, with a majority of them depending on BCL-XL (9/20, 45%), while some depended on a combination of BCL-XL and BCL-2 (3/20, 15%), and only a few depended on BCL-2 (2/20, 10%) or MCL-1 (2/20, 10%), as indicated by their sensitivity to these specific inhibitors (Fig. 1b). One cell line (H211) was found to be sensitive to all of these inhibitors indicating that all three, i.e., BCL-XL, BCL-2, and MCL-1 are important for its survival. These findings are corroborated by the transcriptomic profiling suggesting that BCL-XL is one of the highly expressed BCL-2 family anti-apoptotic proteins, and therefore, a promising therapeutic target in SCLC tumors [10,11,12]. Further, we evaluated the activity of our BCL-XL PROTAC degrader DT2216 on the viability of these SCLC cell lines where 50% (10/20) cell lines were found to be sensitive to DT2216 with an EC50 of <1 µM. All of the cell lines that were found to be sensitive to the BCL-XL inhibitor were sensitive to DT2216 as well. Interestingly, the H1059 cell line was not sensitive to the BCL-XL inhibitor but was found to be sensitive to DT2216. Six of the cell lines did not respond to any of these inhibitors or DT2216 suggesting that these may co-depend on a combination of either BCL-XL/MCL-1 or BCL-2/MCL-1 or BCL-XL/BCL-2/MCL-1 (Fig. 1b). These results suggest that BCL-XL is a key pro-survival protein in SCLC and DT2216 might have a broad-spectrum antitumor activity than a BCL-XL inhibitor in killing BCL-XL-dependent SCLC cells.
A combination of MCL-1 inhibitor with BCL-XL inhibitor or PROTAC is not selective to tumor cells
In the BH3 mimetic screening, SCLC cell lines showed varying responses to the inhibitors of different BCL-2 family anti-apoptotic proteins. Based on these dependencies, we divided SCLC cell lines into different categories; 1) primarily dependent on BCL-XL (such as H1963), 2) mainly dependent on BCL-2 (such as H889), 3) mostly dependent on MCL-1 (such as H209), 4) BCL-XL and BCL-2 co-dependent (such as H1059), 5) BCL-XL and MCL-1 co-dependent (such as H378), and 6) BCL-XL, BCL-2, and MCL-1 dependent (such as H211) (Fig. 2a). When two or more proteins were needed to be simultaneously inhibited in order to sensitize a particular cell line, we called it co-dependent on those proteins. For example, H1059 cells were only sensitive upon simultaneous inhibition of BCL-XL and BCL-2 using navitoclax, therefore, we categorized them as BCL-XL and BCL-2 co-dependent. Similarly, H378 cells were sensitive to simultaneous inhibition of BCL-XL and MCL-1, and therefore, categorized as BCL-XL/MCL-1 co-dependent. These results indicate that SCLC cells are heterogeneous in their dependencies on BCL-2 anti-apoptotic proteins.
Next, we focused on targeting BCL-XL and MCL-1 co-dependent cells, as these types of SCLC tumors are highly resistant to chemotherapy and cannot be safely eradicated with the currently available inhibitors of BCL-2 family proteins because the combination of BCL-XL and MCL-1 inhibitors causes severe normal tissue toxicities and lethality in mice [23, 24, 26]. This was confirmed by our study showing that a combination of DT2216 or A1155463 with MCL-1 inhibitor (S63845) synergistically kills not only tumor cells (Fig. 2b), but also normal cells from different tissue origins such as human bronchial epithelial cells (NHBE), colon fibroblasts (CCD-18Co) and lung fibroblasts (WI38) (Fig. 2c; supplementary Fig. 1a). Of note, S63845 treatment alone was also highly toxic to NHBE cells, which indicates that these cells primarily depend on MCL-1 for survival. These findings do not support using the combination of a BCL-XL inhibitor/PROTAC and an MCL-1 inhibitor to treat BCL-XL and MCL-1 co-dependent SCLC in the clinic.
DT2216+AZD8055 combination synergistically kills BCL-XL/MCL-1 co-dependent SCLC cells through degradation of BCL-XL and suppression of MCL-1 expression, respectively, in a tumor cell-selective manner
Next, we sought to identify a strategy to selectively suppress MCL-1 expression in SCLC cells by rationally targeting certain tumorigenic proteins/pathways. We screened several clinical-stage compounds and FDA-approved drugs including doxorubicin (a topoisomerase II inhibitor and a commonly used chemotherapeutic), SNS-032 (a promiscuous cyclin-dependent kinase [CDK] inhibitor that primarily targets CDK9), AZD8055 (an ATP-competitive catalytic mTORC1/2 inhibitor), TD-19 (a cancerous inhibitor of protein phosphatase 2A inhibitor) and piperazine (a protein phosphatase 2A [PP2A] activator). All of these therapeutic agents have previously been shown to suppress MCL-1 expression through different mechanisms [10, 26,27,28,29]. Here, we aimed to determine whether any of these agents could selectively suppress MCL-1 expression in tumor cells while having minimal/no significant effect on the expression of MCL-1 in normal cells. In agreement with previous reports, doxorubicin, SNS-032 and AZD8055 caused significant suppression of MCL-1 expression in all tested SCLC cell lines (Fig. 3a; Supplementary Fig. 1b). Among these inhibitors tested, only AZD8055 showed minimal effect on the expression of MCL-1 in normal cells (Fig. 3b; Supplementary Fig. 1c). None of these agents, except SNS-032, significantly altered BCL-XL or BCL-2 levels in both tumor cells as well as normal cells. Further, we analyzed the dose-dependent effect of AZD8055 on the expression of MCL-1, BCL-XL, and BCL-2 in H378 and H1048 SCLC and NHBE normal cells. AZD8055 caused dose-dependent suppression of MCL-1 expression in tumor cells without any observable effect in normal cells. As expected, AZD8055 had no observable effects on the expression of BCL-XL and BCL-2 in all the tested cell lines. Of note, BCL-2 expression was not detected in NHBE cells via immunoblotting. Also, AZD8055 dose-dependently inhibited activation of the mTOR downstream targets, i.e., p-4EBP1 and p-S6, in both SCLC and NHBE cells indicating a desired on-target effect (Fig. 3c, d).
Since AZD8055 was found to selectively suppress MCL-1 expression in SCLC cells, we next evaluated it in combination with DT2216 on the viability of BCL-XL/MCL-1 co-dependent SCLC cells as well as normal cells. Out of 11 SCLC cell lines that were resistant to BCL-XL inhibitor (A1155463) alone in Fig. 1b, we selected the five most resistant cell lines to test against the combination of BCL-XL inhibitor and MCL-1 inhibitor. Out of these five, three cell lines (H378, H1048, and DMS53) were found to be sensitive to dual BCL-XL and MCL-1 inhibition. Further, we used the two most sensitive (H378 and H1048) cell lines to test the combination of DT2216 and AZD8055. The DT2216 + AZD8055 combination was found to synergistically inhibit the viability of H378 and H1048 SCLC cells, but not normal NHBE and CCD-18Co cells, as assessed by CI values at EC75 (concentration with 75% viability loss) and EC90 (concentration with 90% viability loss) using Chou-Talalay method  (Fig. 4a, b; Supplementary Fig. 1d). Notably, AZD8055 treatment alone led to partial inhibition of H1048, NHBE, and CCD-18Co cell viability which mainly attributed to its antiproliferative effects. Importantly, the combination of DT2216 and AZD8055 caused a complete loss of viability of tumor cells, but not normal cells. Therefore, the combination effects were synergetic in tumor cells, but not in normal cells, as indicated by the CI values. DT2216 treatment induced a dose-dependent BCL-XL degradation in H1048 cells as expected (Supplementary Fig. 2). Since 1 µM of DT2216 was found to completely deplete BCL-XL, we selected this concentration for further in vitro experiments. In addition, we found that the combination of DT2216 and AZD8055 was more effective compared to individual agents in inhibiting H1048 cell survival and inducing apoptosis by performing the long-term clonogenic assay and flow cytometric analysis, respectively (Supplementary Fig. 3a, b). Furthermore, the DT2216 + AZD8055 combination profoundly induced PARP cleavage compared to individual agents in tumor cells, but not in NHBE cells, which again confirmed the tumor cell-selectivity of the combination (Fig. 4c, d).
Unlike AZD8055 which inhibits both mTORC1 and mTORC2, everolimus is a rapamycin derivative and a selective mTORC1 inhibitor. Everolimus is FDA-approved for use as an immunosuppressant and for treating certain tumors. We wondered whether everolimus can also synergistically kill BCL-XL/MCL-1 co-dependent SCLC cells when combined with DT2216. Indeed, the combination of everolimus and DT2216 synergistically reduced the viability of H378 and H1048 cells, as well as more effectively induced apoptosis compared to individual agents in H1048 cells (Supplementary Fig. 4a, b). However, unlike AZD8055, everolimus alone was less effective in inhibiting the viability of H1048 cells, which might be because it caused even lesser apoptosis compared to AZD8055 (Supplementary Fig. 3b, 4b). This was accompanied by a significant reduction in MCL-1 expression in H1048 cells after everolimus treatment (Supplementary Fig. 4c). These results suggest that the tumor-specific inhibition of only mTORC1 is sufficient for the suppression of MCL-1 expression. Also, mTOR seems to differentially regulate MCL-1 in tumor and normal cells, therefore we could not see MCL-1 downregulation even after efficient mTOR inhibition in NHBE cells.
To gain further insights into the mechanism of synergistic activity of DT2216 + AZD8055, we performed a co-immunoprecipitation (co-IP) analysis of MCL-1 and BIM because BIM acts as a BH3-only pro-apoptotic protein that can trigger apoptosis by activating the apoptotic effectors BAX and BAK and the sequestration of BIM by MCL-1 or BCL-XL inhibits apoptosis . Since BIM is known to bind both BCL-XL and MCL-1, we hypothesized that the degradation of BCL-XL with DT2216 may lead to an increased association of BIM with MCL-1, and co-treatment with DT2216 + AZD8055 may disrupt this interaction. In line with our hypothesis, we found that DT2216 treatment increases the BIM/MCL-1 association which was disrupted when the cells were treated with the DT2216 + AZD8055 combination (Fig. 4e). Interestingly, increased BIM binding seems to stabilize MCL-1 upon DT2216 treatment, and the MCL-1 levels are suppressed in the combination-treated cells. Since BCL-XL inhibition has been shown to increase MCL-1 levels in some cancer cell lines as a compensatory mechanism . So, the increased MCL-1 levels upon DT2216 treatment may be due to either BIM-induced stabilization and/or a compensatory mechanism that needs further exploration.
DT2216+AZD8055 combination synergistically inhibits tumor growth in SCLC xenograft and PDX models
To further assess the combined mTOR inhibition and BCL-XL degradation as a potential therapeutic strategy for BCL-XL and MCL-1 co-dependent SCLC, we first investigated the efficacy of DT2216 + AZD8055 combination using the H1048 xenograft tumor model. In agreement with the in vitro results, DT2216 alone had no effect on H1048 tumor growth. Although AZD8055 alone showed some efficacy, the effect was not significant. On the other hand, the combination of DT2216 and AZD8055 led to significant inhibition of tumor growth (Fig. 5a). More importantly, the combination treatment appeared to be safe as indicated by no significant change in mouse body weights after the treatment (Fig. 5b). In addition, we did not observe any gross organ toxicities upon necropsy in mice treated with DT2216 + AZD8055. Furthermore, the combination caused a similar reduction (25–30%) in platelets as DT2216 alone, where platelet counts remained well above 2 × 105 per µL of blood (Fig. 5c). Notably, platelet counts above 2 × 105 per µL of blood in mice (equivalent to 5 × 104 per µL in humans) are not associated with a significant risk of hemorrhage and considered to be clinically safe . Therefore, a 25–30% reduction in total platelet count may likely not be of any clinical concern. Next, we confirmed that DT2216 and AZD8055 led to a significant reduction in BCL-XL and MCL-1 levels, respectively, which was associated with significant inhibition of mTOR substrates (p-4EBP1 and p-S6) upon AZD8055 treatment in H1048 tumor lysates. Interestingly, the combination also caused a significant decrease in BCL-2 protein levels in these tumor samples (Fig. 5d, e).
Since the PDX models better recapitulate human cancers in vivo, we next evaluated the effect of the combination of DT2216 + AZD8055 in the LX47-SCLC PDX model. We found that the combination significantly inhibited tumor growth in this PDX model of SCLC, whereas single agents failed to have significant effects(Fig. 5f). Again, we did not observe any significant body weight loss with the combination treatment in these mice (Fig. 5g).
DT2216+AZD8055 combination inhibits lung tumor growth and increases mice survival in the Rb1/p53/p130 GEM model
Next, we used the conditional-mutant Rb1/p53/p130 mouse model of SCLC to test the efficacy of the DT2216 + AZD8055 combination. In these mice, Rb1, Tp53, and p130 tumor suppressor genes have flanking lox sequences that are under the control of Cre recombinase. These genes are deleted upon administration of Adenovirus (Ad5CMVCre-eGFP), specifically in the lung epithelial cells, and lead to tumor formation in the lungs [33, 34]. Since the Rb1/p53/p130 mouse tumors closely resemble human SCLC, it is a suitable preclinical mouse model to evaluate newer therapeutics against SCLC. We determined a mean tumor onset time of 110 days after administration of adenovirus titer of 2.5 × 107 pfu/mouse to induce the formation of small visible tumor nodules in the mouse lungs. Therefore, we started treating the mice after 110 days with DT2216 and/or AZD8055 for up to 150 days (Fig. 6a). We did not include the DT2216 alone group because DT2216 was not found to have any significant effect on tumor growth when used alone in this model in a previous study as shown in Fig. 6e. Mice were euthanized, and the survival was recorded at the humane endpoint when the body condition score of animals declined . At the end of the experiment i.e, 150 days after treatment, 2/8 (25%), 2/8 (25%) and 4/7 (~57%) mice were alive in the vehicle, AZD8055, and combination-treatment groups, respectively. The median survival time was 131, 149.5, and >166 days in the vehicle, AZD8055, and the combination-treatment group, respectively (Fig. 6b). We excised the lungs from these mice and observed that the combination-treated lungs had much smaller tumor nodules as compared to vehicle or AZD8055 treatments (Fig. 6c). Moreover, the number of total tumor nodules per lungs was also significantly reduced in the combination-treated mice (Fig. 6d). The histopathological staining in the lungs from a separate experiment further evidenced the reduction in tumor burden in the combination-treated mice (Fig. 6e). We did not see any significant changes in the lungs, spleen, liver, or kidney weights after combination treatment (Supplementary Fig. 5a). The reductions in spleen weight in AZD-treated mice might be attributable to the immunosuppressive effect of mTOR inhibitors. DT2216 might be able to reduce the immunosuppressive effect of mTOR inhibition in part via depleting tumor-infiltrating regulatory T cells (TI-Tregs) as shown in our recent study . Depletion of TI-Tregs by DT2216 may stimulate antitumor immunity and attenuate mTOR inhibition-induced immunosuppression and spleen size reduction. Furthermore, we did not see any clinically significant reduction in platelets and other blood cell counts in the treatment cohorts (Supplementary Fig. 5b, c). Overall, these results suggest that the DT2216 + AZ8055 combination may be a promising therapeutic strategy, particularly against BCL-XL/MCL-1 co-dependent SCLC, and therefore this combination could potentially be tested in clinical trials in the future.
SCLC shows high inter- and intra-tumoral heterogeneity which is primarily responsible for the therapeutic resistance [6,7,8,9]. This heterogeneity is in part attributed to an aberrant expression of anti-apoptotic BCL-2 family proteins which are crucial for the survival of SCLC cells [10,11,12]. In the present study, we first established the survival dependence of SCLC cell lines on different BCL-2 family anti-apoptotic proteins using BH3 mimetic screening. We found that most SCLC cell lines are dependent on BCL-XL for their survival and are highly sensitive to a BCL-XL inhibitor or our recently developed BCL-XL PROTAC DT2216 (now a clinical candidate in the phase-I trial) [16, 17]. On the other hand, some SCLC cell lines were found to be dependent on multiple co-expressed BCL-2 family proteins such as concurrent BCL-XL and BCL-2, or concurrent BCL-XL and MCL-1. BCL-XL/BCL-2 co-dependent cell lines could be targeted with navitoclax, however, the clinical translation of navitoclax is hampered by dose-limiting on-target toxicity of thrombocytopenia [14, 15]. More importantly, BCL-XL/MCL-1 co-dependent tumor cells cannot be safely targeted with the currently available inhibitors because the combination of BCL-XL and MCL-1 inhibitors causes severe tissue damage and lethality in mice [22,23,24]. Therefore, finding a strategy to selectively target BCL-XL and MCL-1 in tumors without causing significant on-target toxicity was the primary goal of our current study for treating an important difficult-to-treat subset of SCLC.
Since systemic MCL-1 inhibition with currently available inhibitors leads to normal tissue toxicity and lethality when combined with a BCL-XL inhibitor/PROTAC, we sought to identify a strategy to selectively suppress MCL-1 expression in SCLC cells. After screening several compounds that target oncogenic pathways known to upregulate MCL-1 [10, 26,27,28,29], we identified that AZD8055, a mTORC1/2 ATP-competitive inhibitor, and everolimus, a selective mTOR1 inhibitor, can selectively suppress MCL-1 expression in SCLC cells but not in normal cells. In contrast, other compounds such as doxorubicin and SNS-032 non-specifically downregulated MCL-1 in tumor cells as well as in normal cells. This was correlated with high basal mTOR activation in MCL-1-dependent SCLC cell lines (data not shown). The mTOR activation has been shown to enhance cap-dependent MCL-1 translation, and therefore, inhibition of mTOR suppresses MCL-1 at post-translational level [26, 28, 29, 37]. Of note, the combination of DT2216 with AZD8055 or everolimus synergistically inhibited the viability and induced apoptosis in BCL-XL and MCL-1 co-dependent SCLC cell lines, but not the normal cells from different tissue origins including lungs and colon.
Our further investigation using different in vivo SCLC models including conventional xenografts, PDX, and Rb1/p53/p130 GEM model also suggests that the combination of DT2216 and AZD8055 can effectively inhibit the SCLC growth in mice. More importantly, the combination appeared to be safe as evidenced by no significant decrease in mouse body weights as well as no clinically significant reduction in different blood cells including platelets, and the absence of any observable tissue pathology. Interestingly, results using the SCLC GEM model, which closely recapitulates genetic heterogeneity found in human SCLC, indicate that the combination of DT2216 + AZD8055 strongly inhibits tumor growth in the lungs and increased the survival of mice. The effectiveness of the combination in the GEM model was encouraging because the tumors in this model have been shown to be highly resistant to cisplatin plus etoposide doublet chemotherapy .
These findings have important clinical implications because tumor-specific targeting of BCL-XL and MCL-1 has high therapeutic value. Two prior studies have found that a combination of navitoclax and AZD8055 synergistically kills different tumor cells from SCLC and BRAF/KRAS-mutated colorectal cancer [26, 28]. Moreover, a study from Dr. Christine Hann’s group has demonstrated synergy between rapamycin and ABT737 (a predecessor compound of navitoclax) against different PDX models of SCLC . In another study, the combined inhibition of BCL-XL and mTOR was found to synergistically induce apoptosis in PIK3CA-mutated breast cancer . However, these studies did not aim to comprehensively evaluate tumor-selectivity and on-target toxicities of this combination (especially in mouse models). Given that BCL-XL inhibitors including navitoclax cause thrombocytopenia, a combination of navitoclax with AZD8055 (or another mTOR inhibitor) may not be clinically feasible [14, 15]. In contrast, by combining AZD8055 with platelet-sparing BCL-XL degrader DT2216, we achieved tumor-selective targeting of both MCL-1 and BCL-XL, respectively, without significant on-target toxicity both in cell culture and in mice. This approach can also be applied to other tumor types which are co-dependent on MCL-1 and BCL-XL [39, 40]. One limitation of our in vitro BH3 mimetic screening is that it requires live cells, so it cannot be used to stratify patients who will benefit from the combination. In that case, a dynamic BH3 profiling assay would be more useful as demonstrated previously [41, 42].
More recently, SCLC tumors have been classified into four molecular subtypes based on the relative expression of four transcriptional regulators, i.e., ASCL1, NEUROD1, POU2F3, and YAP1 [5, 7]. Each of these molecular subtypes shows distinct therapeutic vulnerabilities [8, 9]. For example, ASCL1-high subtype (classic or neuroendocrine (NE) SCLC)  has been shown to be sensitive to BCL-2 inhibition with ABT263 . Interestingly, we observed that most variant-SCLC cells (non-NE consisting of POU2F3 and/or YAP1 subtype)  were dependent on the co-expression of BCL-XL and MCL-1. Although these subtypes are not being used to direct treatment decisions for SCLC at present, we expect that POU2F3 and/or YAP1 SCLC subtypes could be better targeted with a combination of DT2216 and an mTOR inhibitor. In this case, immunohistochemical or proteomics profiling of four of these transcriptional regulators could be a better alternative to BH3 profiling for stratifying patients who can specifically benefit from the DT2216 + mTOR inhibitor combination. In the current study, we used AZD8055 as a proof of concept, but it would be suitable to use an FDA-approved mTOR inhibitor (such as everolimus) in combination with DT2216 in clinical trials.
In conclusion, the findings from our in vitro and in vivo studies suggest that the combination of DT2216 + AZD8055 is synergistic and somewhat tumor-selective against the BCL-XL/MCL-1 co-dependent subset of SCLC and is tolerable in mice without appreciable on-target toxicity and normal tissue injury. These findings may have a high potential for near-term clinical translation as the combination of DT2216 and an FDA-approved mTOR inhibitor (such as everolimus) can be rapidly evaluated in SCLC patients, given that DT2216 is already in the phase-I clinical trial (Identifier: NCT04886622). This kind of approach can help to effectively treat an important and difficult-to-treat subset of SCLC patients in the near future.
Materials and methods
Cell lines and culture
All the SCLC cell lines, except DMS53 and DMS114, were obtained from the original NCI-Navy Medical Oncology source supply . DMS53 and DMS114 SCLC cell lines, CCD-18Co normal colon fibroblasts, and WI-38 lung fibroblasts were purchased from the American Type Culture Collection (ATCC, Manassas, VA). SCLC cell lines were cultured in RPMI-1640 medium (Cat. No. 22400–089, Thermo Fisher, Waltham, MA). CCD-18Co and WI-38 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Cat. No. 12430-062, Thermo Fisher). The culture media were supplemented with 10% heat-inactivated fetal bovine serum (FBS, Cat. No. S11150H, Atlanta Biologicals, GA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Pen-Strep, Cat. No. 15140122, Thermo Fisher). NHBE cells were purchased from Lonza (Cat. No. CC-2541, Basel, Switzerland), and were cultured in Lonza’s bronchial epithelial cell growth medium (Cat. No. CC-3170) with supplements and growth factors (CC-4175). The stocks of NCI SCLC cell lines that we used were STR profiled by NIH, so the authenticity of the cell lines remained preserved. All cultures were confirmed for Mycoplasma negativity using the MycoAlert Mycoplasma Detection Kit (Cat. No. LT07–318). All the cell lines were maintained in a humidified incubator at 37 °C and 5% CO2.
DT2216 was synthesized in Dr. Guangrong Zheng’s laboratory (University of Florida, Gainesville, FL) according to the previously described protocol . AZD8055 (Cat. No. HY-10422) and everolimus (Cat. No. HY-10218) were purchased from MedChemExpress (Monmouth Junction, NJ). A1155463 (Cat. No. S7800), ABT199 (Cat. No. S8048), S63845 (Cat. No. S8383), and ABT263 (Cat. No. S1001) were purchased from SelleckChem (Houston, TX).
Cell viability assays
The cell viability was measured by MTS assay according to the manufacturer’s protocol (Cat. No. G-111, Promega, Madison, WI) and as described previously [16, 39]. EC50 values were determined using GraphPad Prism software (GraphPad Software, La Jolla, CA).
BH3 mimetic screening
The screening was performed to determine the survival dependence of SCLC cells on different BCL-2 family anti-apoptotic proteins . The cells were treated in 96-well plates with either a specific inhibitor of BCL-2 family anti-apoptotic proteins such as A1155463 (selective BCL-XL inhibitor), venetoclax (selective BCL-2 inhibitor), and S63845 (selective MCL-1 inhibitor), or a non-specific inhibitor such as navitoclax (BCL-XL/BCL-2 dual inhibitor). Thereafter, the viability was assessed using the MTS assay as described above.
Cell pellets were lysed in the Pierce IP lysis buffer (Cat. No. 87787; Thermo Fisher) supplemented with protease and phosphatase inhibitors as described previously [16, 39]. The supernatants were collected and precleared by incubating with 1 µg of mouse anti-IgG (Cat. No. sc-2025; Santa Cruz Biotechnology [SCB], Dallas, TX) and 20 µL of protein A/G-PLUS agarose beads (Cat. No. sc-2003; SCB) for 30 min at 4 °C. The supernatants containing 1 mg of protein were incubated with 2 µg of anti-MCL-1 (Cat. No. sc-12756; SCB) or anti-IgG antibody overnight followed by incubation with 25 µL protein A/G agarose beads for 1–2 h at 4 °C. Thereafter, the immunoprecipitates were collected by centrifugation, washed three times with IP lysis buffer, mixed with 50 µL of Laemmli’s SDS-buffer, denatured and then subjected to immunoblot analysis for BIM and MCL-1. Anti-rabbit HRP-conjugated Fc fragment-specific secondary antibody (Cat. No. 111-035-046, dilution 1:10000, Jackson ImmunoResearch, West Grove, PA) was used to detect immune complexes in immunoblotting.
Cell line-derived xenograft and PDX studies
All the animal procedures were performed in accordance with the rules of IACUC. CB-17 SCID-beige mice (5–6 weeks old) were purchased from the Charles River Laboratories (Wilmington, MA). NCI-H1048 (H1048) tumor cells at a density of 2.5 × 106 per mouse in 50% Matrigel (Cat. No. 356237, Corning, Corning, NY), and PBS mixture were injected subcutaneously (s.c.) into the right flank region of the mice as described previously [16, 39]. Tumor size was measured twice a week with digital calipers and tumor volume was calculated using the formula (Length × Width2 × 0.5). The mice were randomized into different treatment groups when the tumors reached ~150 mm3 (n = 5–6 mice per group). Mice were treated with vehicle, AZD8055 (16 mg/kg, 5 days a week, p.o.), DT2216 (15 mg/kg, every four days [q4d], i.p.), and a combination of AZD8055 and DT2216. AZD8055 was formulated in 10% (v/v) DMSO, and 90% of 20% (w/v) Captisol (Cat. No. NC0604701, Cydex Pharmaceuticals a Ligand Company, San Diego, CA, USA) in normal saline and DT2216 was formulated in 50% phosal 50 PG, 45% miglyol 810 N and 5% polysorbate 80. Mice were euthanized when they became moribund, or their tumor sizes reached a humane endpoint as per Institutional Animal Care and Use Committee (IACUC) policy. For euthanasia, animals were sacrificed by CO2 suffocation followed by cervical dislocation. The tumors were subsequently harvested, lysed, and used for immunoblot analysis.
The PDX experiments were performed at Johns Hopkins University. NOD-SCID IL2Rgammanull (NSG) mice aged 5–6 weeks were purchased from the Jackson Laboratory (Stock No. 005557, Bar Harbor, Maine, USA). LX47 SCLC PDX model was established and characterized by Dr. Christine Hann’s lab at the Johns Hopkins University and was propagated in NSG mice as reported previously . The tumors were harvested after they reached 1500 mm3 and cut into ~2–3 mm fragments and were implanted s.c. after submerging in Matrigel in additional NSG mice . The animals were randomized into different treatment groups when the tumors reached 100–200`mm3 and were treated as described above (n = 8–9 mice per group). The tumor volumes were normalized with their baseline readings on day 1 of treatment and are presented as normalized tumor volumes. The number of mice per group for all animal studies was determined based on our own previous experience as these numbers of mice are sufficient to observe significant differences among different groups.
Tumor induction and treatments in Rb1/p53/p130 GEM model
The Rb1loxP/loxP p53lox/loxP p130lox2722/lox2722 mouse strain was provided by Dr. Maria Zajac-Kaye (University of Florida) [33, 34]. The presence of floxed sequences (loxP and lox2722) was confirmed by PCR as described previously . Tumors were initiated when mice were 6–8 weeks of age by nasal inhalation of adenovirus serotype 5 expressing Cre-recombinase fused to enhancer GFP under a CMV promoter (Ad5CMVCre-eGFP, University of Iowa Vector Core, Cat. No. WC-U of Iowa 1174) at 2.5 × 107 pfu/mouse. Drug treatments were started 110 days after Ad-Cre delivery, which was the timing to be required for the onset of SCLC tumorlets. Mice were treated with vehicle, AZD8055 (16 mg/kg, 5 days a week, p.o.), and a combination of DT2216 (15 mg/kg, q4d, i.p.) and AZD8055 (n = 7–8 mice per group). Survival events were scored when the body condition score (as defined by the American Association for Laboratory Animal Science) of animals declined or per absolute survival events . The lungs were excised upon euthanizing the individual mice, stained in Bouins’ solution, and photographed as described previously [45, 46]. The number of visible tumor nodules was counted on the surface of each pair of lungs and is presented as the average number of tumor nodules/lungs.
All the graphs presented in this manuscript were made and statistical analyses were performed using the GraphPad Prism-9 software. A two-sided unpaired Student’s t test was used for comparisons between the means of the two groups. P < 0.05 was considered to be statistically significant. The combination index (CI) was calculated using Compusyn software (https://www.combosyn.com/) based on the Chou–Talalay method . CI < 1 indicates a synergistic effect, CI = 1 indicates an additive effect and CI > 1 indicates an antagonistic effect. CDI < 0.7 indicates a significant synergistic effect.
Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:765.
Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12:47.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9.
Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619–30.
Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, et al. New approaches to SCLC therapy: from the laboratory to the clinic. J Thorac Oncol. 2020;15:520–40.
Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423–36.
Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289–97.
Pozo K, Kollipara RK, Kelenis DP, Rodarte KE, Ullrich MS, Zhang X, et al. ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer. iScience. 2021;24:102953.
Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346–360.e7.
Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, et al. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun. 2017;8:16078.
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–8.
Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 2008;14:3268–77.
Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163–9.
Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118:1663–74.
Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14:943–51.
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938–47.
He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020;13:95.
Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, et al. Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020;192:112186.
Zhang P, Zhang X, Liu X, Khan S, Zhou D, Zheng G. PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors. Explor Target Antitumor Ther. 2020;1:259–72.
He Y, Zhang X, Chang J, Kim HN, Zhang P, Wang Y, et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020;11:1996.
Soderquist RS, Crawford L, Liu E, Lu M, Agarwal A, Anderson GR, et al. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. Nat Commun. 2018;9:3513.
Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27:1365–77.
Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology 2009;50:1217–26.
Weeden CE, Ah-Cann C, Holik AZ, Pasquet J, Garnier JM, Merino D, et al. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. Oncogene 2018;37:4475–88.
George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47–53.
Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci USA. 2015;112:E1288–96.
Elgendy M, Cirò M, Hosseini A, Weiszmann J, Mazzarella L, Ferrari E, et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3β-MCL-1 Axis. Cancer Cell. 2019;35:798–815.e5.
Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 2014;4:42–52.
Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, et al. The mTORC1/2 inhibitor AZD8055 strengthens the efficiency of the MEK inhibitor trametinib to reduce the Mcl-1/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737. Mol Cancer Ther. 2017;16:102–15.
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27–55.
Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175–93.
Lee Y-C, Wang L-J, Huang C-H, Shi Y-J, Chang L-S. ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells. Cancer Lett. 2018;432:191–204.
Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 2010;70:3877–83.
Kellish P, Shabashvili D, Rahman MM, Nawab A, Guijarro MV, Zhang M, et al. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. J Clin Invest. 2019;129:2279–92.
Ullman-Culleré MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49:319–23.
Kolb R, De U, Khan S, Luo Y, Kim M-C, Yu H, et al. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021;12:1281.
Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, et al. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Sci Transl Med. 2016;8:369ra175.
Gardner EE, Connis N, Poirier JT, Cope L, Dobromilskaya I, Gallia GL, et al. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res. 2014;74:2846–56.
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, et al. Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL-specific degrader DT2216. Mol Cancer Ther. 2022;21:184–92.
Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019;10:342.
Del Gaizo Moore V, Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332:202–5.
Fraser C, Ryan J, Sarosiek K. BH3 profiling: a functional assay to measure apoptotic priming and dependencies. Methods Mol Biol. 2019;1877:61–76.
Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA. 2014;111:14788–93.
Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, et al. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996;24:32–91.
Khan S, Shukla S, Farhan M, Sinha S, Lakra AD, Penta D, et al. Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis. Life Sci. 2020;256:117976.
Khan S, Shukla S, Sinha S, Lakra AD, Bora HK, Meeran SM. Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. Int J Biochem Cell Biol. 2015;58:1–16.
This study was supported in part by US National Institutes of Health (NIH) grant R01 CA242003 (DZ & GZ), R01 CA241191 (DZ & GZ), R01 CA219836 (DZ), R01 CA260239 (DZ & WZ) and Florida Department of Health grant 8JK04 (FJK and MZ-K).
SK, DT, PZ, GZ, and DZ are inventors of two patent applications for use of BCL-XL PROTACs as senolytic and antitumor agents. RH, GZ, and DZ are co-founders of and have equity in Dialectic Therapeutics, which develops BCL-XL/2 PROTACs to treat cancer.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Khan, S., Kellish, P., Connis, N. et al. Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discov. 9, 1 (2023). https://doi.org/10.1038/s41420-022-01296-8